He went from a rural school in Colombia, South America, to become a world-class #TransplantSurgeon at Northwestern Medicine. Juan Carlos Caicedo, MD, shares his story for #HispanicHeritageMonth. #NMBetter
1/ 🧵 Después de 75 años de usar glucocorticoides (GC) para la nefritis lúpica (NL), todavía no sabemos cuáles son las dosis más efectivas y seguras. Vamos a explorar los datos de nuestra reciente publicación: https://t.co/AsZknaQ01s
Have you ever wonder why so many clinical trials have failed in lupus? 🤔
1/8 🧵
Have a look into our new paper, where we explored the (statistical) fragility of RCTs for #SLE and #lupus#nephritis!
https://t.co/mN1yNCZhhz
Additive effects of dapagliflozin ➕ finerenone on albuminuria in non-diabetic CKD: an open-label randomized clinical trial ca. 2024 from @CKJsocial#Nephpearls
https://t.co/5wnDC9DUxe
KDIGO is pleased to announce the publication of the 2024 Clinical Practice Guideline for the Management of Lupus Nephritis, published today in the January 2024 issue of Supplement to Kidney International, with an Executive Summary published in the main pages of the journal.
Read the news release: https://t.co/hd8O3bCSEY
Read the guideline in Kidney International: https://t.co/reqtpXWFk8
Download the guideline: https://t.co/Kqcmmu929y
Developed under the stewardship of Co-Chairs Brad Rovin, MD (US) and Jürgen Floege, MD (DE), this guideline is an update of the Lupus Nephritis (LN) chapter of the KDIGO 2021 Glomerular Diseases Guideline.
"We are thrilled to publish the Lupus Nephritis Guideline, which follows only two years after the publication of the KDIGO Glomerular Diseases Guideline and reflects the latest advancements in the field,” said Dr. Rovin. "This guideline offers critical insights into navigating the complexities of LN treatment, especially with the introduction of novel therapies, and highlights the need for individualized therapy selection based on patient-specific factors and clinical scenarios. With ongoing trials evaluating additional novel therapeutics and promising new data on the horizon, the guideline sets the stage for future advancements in the management and treatment of LN.”
"This guideline includes several key updates to inform clinical decision-making, leveraging the latest evidence to integrate new treatments into the arsenal of established clinical standards,” said Dr. Floege. “A section on chronic kidney disease progression in LN underscores the importance of addressing broader kidney health concerns beyond acute treatment. We hope the rigorous research, clinical insights, and collective expertise represented in this guideline will help improve outcomes for those affected by this challenging condition.”
KDIGO thanks the Guideline Work Group for their dedication and expertise and the Evidence Review Team from Brown University School of Public Health for their comprehensive work on this guideline.
#lupus #lupusnephritis
La #xénotransplantation fait l’actualité, et notre étude vient de sortir dans @TheLancet 💪 🚀
Un grand merci 🙏 aux médias de relayer notre travail ainsi qu’à nos tutelles de soutenir nos projets et de diffuser nos résultats.
👇 👇 👇
Hi #MedTwitter!
I´m Nelson Martinez Merizalde, a medical graduate at @UPC_edu. I am applying to internal medicine in #match2024 & I´m passionate about #meded, research. I love to travel, dogs, star wars and a good glass of wine.
Looking forward to connect with mentors and peers.